StockData

Relay Therapeutics vs X4 Pharmaceuticals

RLAY and XFOR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How RLAY and XFOR compare

Relay Therapeutics is the larger company, worth 13 times as much as X4 Pharmaceuticals ($3.8B against $281M).

X4 Pharmaceuticals grew revenue faster over the last twelve months (73.7% versus 23.9% for Relay Therapeutics).

X4 Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of −813% compared with −2764% at Relay Therapeutics.

Relay Therapeutics scores higher on the StockData Score (10 against 4 for X4 Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricRLAYXFOR
Size and price
Market cap$3.8B$281M
Share price$17.27$2.83
Change, 1 year168%−24.1%
Change, 5 years−42.1%−97.9%
Beta (5Y)1.891.57
Employees19245
StockData Score
Total score10 (better)4
Valuation score01 (better)
Growth score22
Performance score2 (better)0
Health score6 (better)1
Dividend score00
Valuation
P/S366×28.3× (better)
P/B4.3×2.0× (better)
Growth
Revenue growth (TTM)23.9%73.7% (better)
Revenue growth, 5Y average−28.6%16.7% (better)
Profitability
Gross margin–68.8%
Operating margin−2999%−812% (better)
Net margin−2764%−813% (better)
Return on equity−36.8% (better)−80.3%
Return on invested capital−37.1%–
Financial health
Debt / equity0.00–
Interest coverage–−9.3×
Current ratio18.27 (better)13.22
Altman Z-score26.22 (better)−2.27
Piotroski F-score44
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions113%103%
Held by insiders24.5%12.2%
Insider net buying, 12 months−$129M−$451K (better)
Superinvestors holding1–
Short interest, % of float26.4%9.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.